Outcomes in Systemic Sclerosis–Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies

2025/04/15 by Elizabeth R. Volkmann, Shervin Assassi, Christopher P. Denton +4 · 1 voice · 1 citation
Medicine · #Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis #Multiple Sclerosis Research Studies #Systemic Sclerosis and Related Diseases

paper · pdf · doi:10.3899/jrheum.2024-1063

openalex publication_date 2025/04/15 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Abstract

OBJECTIVE: We aimed to compare the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) based on serological status. METHODS: In a posthoc analysis of the SENSCIS trial (nintedanib vs placebo in SSc-ILD; ClinicalTrials.gov: NCT02597933), we analyzed the rate of decline in forced vital capacity (FVC) over 52 weeks in 3 subsets: (1) positive for anticentromere antibody (ACA), (2) positive for anti-RNA polymerase III antibody (ARA), and (3) negative for ACA, ARA, and antitopoisomerase I antibody (ATA). RESULTS: Among study participants who underwent baseline serological evaluation, 32/549 (5.8%) were ACA positive, 98/528 (18.6%) were ARA positive, and 127/526 (24.1%) were negative for ACA, ARA, and ATA. Among the serological subsets of interest, in the placebo arm, the adjusted rate (standard error) of decline in FVC was -31.2 (41.5) mL/year among participants who were positive for ACA and -64.7 (35.1) mL/year among participants who were positive for ARA, numerically lower than in the overall SENSCIS trial population (-93.3 [13.5] mL/yr). However, participants who were negative for ACA, ARA, and ATA experienced a numerically greater rate of decline in FVC than the overall trial population, both in those randomized to placebo (-115.6 [35.4] mL/yr vs -93.3 [13.5] mL/yr) and those randomized to nintedanib (-91.8 [34.3] mL/yr vs -52.4 [13.8] mL/yr). CONCLUSION: These analyses of data from the SENSCIS trial suggest that patients with SSc-ILD who are ACA positive or ARA positive can experience progression of SSc-ILD. Patients negative for ACA, ARA, and ATA had a higher rate of progression than the overall trial population and should be monitored closely.

Cited by

• Personalizing Management of Systemic Sclerosis–Associated Interstitial Lung Disease: Are Autoantibodies the Key for Risk Stratification?

Discussions

• Research Article Outcomes in Systemic Sclerosis–Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies 📖 doi.org/10 [bsky, 1 points, 0 comments]

Related

• Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis
• A screening tool to detect interstitial lung disease in systemic sclerosis: the ILD-RISC Score
• Clinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study)
• ERS/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease
• ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung diseaseDeveloped by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR)Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)